Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Myxofibrosarcoma (MFS) is an aggressive sarcoma with a highly complex karyotype. Complete resection is the only curative treatment for MFS because it is refractory to chemotherapy. To improve clinical outcomes, it is critical to develop novel treatments for MFS. Although patient-derived cell lines play a key role in cancer research, only 12 MFS cell lines have been reported to date, and considering the diversity of the disease, more cell lines need to be established. Hence, in the present study, we established a novel MFS cell line, NCC-MFS4-C1, using a surgically resected tumor tissue from a patient with MFS. NCC-MFS4-C1 cells exhibited copy number alterations similar to those of the original tumors and showed constant proliferation, spheroid formation, and aggressive invasion. By screening a drug library, we found that actinomycin D, bortezomib, docetaxel, eribulin, and romidepsin significantly reduced the proliferation of NCC-MFS4-C1 cells. Therefore, the NCC-MFS4-C1 cell line may be a useful resource for researching MFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Board WCoTE. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–185

  2. Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol. 2018;36:160–7.

    Article  CAS  Google Scholar 

  3. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715–21.

    Article  CAS  Google Scholar 

  4. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the lowgrade variant. Am J Surg Pathol. 1996;20:391–405.

  5. Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720–5.

    Article  Google Scholar 

  6. Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016;25:775–88.

    Article  Google Scholar 

  7. Iwata S, Yonemoto T, Araki A, et al. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol. 2014;110:707–11.

    Article  Google Scholar 

  8. Waters B, Panicek DM, Lefkowitz RA, et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol. 2007;188:W193–8.

    Article  Google Scholar 

  9. Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012:830879.

  10. Lee AY, Agaram NP, Qin LX, et al. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann Surg Oncol. 2016;23:818–25.

    Article  Google Scholar 

  11. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35:612–21.

    Article  Google Scholar 

  12. Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518–27.

    Article  Google Scholar 

  13. Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80–6.

    Article  Google Scholar 

  14. Saito S, Morita K, Kohara A, et al. Use of BAC array CGH for evaluation of chromosomal stability of clinically used human mesenchymal stem cells and of cancer cell lines. Hum Cell. 2011;24:2–8.

    Article  Google Scholar 

  15. Tseng YY, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Curr Opin Genet Dev. 2019;54:33–40.

    Article  CAS  Google Scholar 

  16. Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019;19:97–109.

    Article  CAS  Google Scholar 

  17. Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151–61.

    Article  CAS  Google Scholar 

  18. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

    Article  CAS  Google Scholar 

  19. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.

    Article  CAS  Google Scholar 

  20. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813–23.

    Article  CAS  Google Scholar 

  21. Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3–13.

    Article  CAS  Google Scholar 

  22. Hattori E, Oyama R, Kondo T. Systematic Review of the Current Status of Human Sarcoma Cell Lines. Cells. 2019;8:157.

    Article  CAS  Google Scholar 

  23. Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  24. Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28–35.

    Article  CAS  Google Scholar 

  25. Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.

    Article  Google Scholar 

  26. Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007;100:339–48.

    Article  CAS  Google Scholar 

  27. Miserocchi G, De Vita A, Mercatali L, et al. Characterization and drug sensitivity of a new high-grade myxofibrosarcoma cell line. Cells. 2018;7.(11):186.

  28. Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.

    Article  Google Scholar 

  29. Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep. 2017;7:44700.

    Article  Google Scholar 

  30. Kito F, Oyama R, Sakumoto M, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214–22.

    Article  CAS  Google Scholar 

  31. Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246–53.

    Article  CAS  Google Scholar 

  32. Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34(4):1266–1273.

  33. Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510–9.

    Article  CAS  Google Scholar 

  34. Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11–5.

    Article  CAS  Google Scholar 

  35. Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561–84.

    Article  CAS  Google Scholar 

  36. Li CF, Wang JM, Kang HY, et al. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res. 2012;18:1598–610.

    Article  CAS  Google Scholar 

  37. Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-Cell lymphoma. J Adv Pract Oncol. 2015;6:22–36.

    PubMed  PubMed Central  Google Scholar 

  38. Kawarazaki A, Horinaka M, Yasuda S, Kawashima H, Numajiri T, Sakai T. The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. J BUON. 2020;25:464–71.

    PubMed  Google Scholar 

Download references

Acknowledgements

We thank Drs. F. Nakatani, E. Kobayashi, S. Fukushima, M. Nakagawa, T. Komatsubara, M. Saito, and C. Sato of the Department of Musculoskeletal Oncology, and Drs. M Arakaki, and Y Suemitsu of the Department of Diagnostic Pathology, National Cancer Center Hospital, for sampling tumor tissue specimens from surgically resected materials. We also appreciate the technical assistance provided by Ms. Y. Kuwata (Division of Rare Cancer Research), and the technical support provided by Ms. Y. Shiotani, Mr. N. Uchiya, and Dr. T. Imai (Central Animal Division, National Cancer Center Research Institute). We would like to thank Editage (www.editage.jp) for help with English language editing and constructive comments on the manuscript. This research was technically assisted by the Fundamental Innovative Oncology Core at the National Cancer Center.

Funding

This research was supported by the Japan Agency for Medical Research and Development (grant number 20ck0106537h0001).

Author information

Authors and Affiliations

  1. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Yuki Yoshimatsu, Rei Noguchi, Ryuto Tsuchiya, Yooksil Sin, Takuya Ono & Tadashi Kondo

  2. Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Jun Sugaya, Shintaro Iwata & Akira Kawai

  3. Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Akihiko Yoshida

Authors
  1. Yuki Yoshimatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rei Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ryuto Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yooksil Sin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takuya Ono
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Sugaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shintaro Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The ethical committee of the National Cancer Center approved the use of clinical materials for this study (approval number 2004–050).

Informed consent

Written informed consent for publication was provided by the patient.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoshimatsu, Y., Noguchi, R., Tsuchiya, R. et al. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Human Cell 34, 1911–1918 (2021). https://doi.org/10.1007/s13577-021-00589-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-021-00589-x

Keywords

Search

Navigation